Rohto Pharmaceutical Co - Stock

Rohto Pharmaceutical Co EBIT 2024

Rohto Pharmaceutical Co EBIT

40.05 B JPY

Ticker

4527.T

ISIN

JP3982400008

WKN

858075

In 2024, Rohto Pharmaceutical Co's EBIT was 40.05 B JPY, a 17.93% increase from the 33.96 B JPY EBIT recorded in the previous year.

The Rohto Pharmaceutical Co EBIT history

YEAREBIT (undefined JPY)
2027e-
2026e-
2025e-
202440.05
202333.96
202229.02
202122.99
202022.56
201920.81
201819.09
201715.45
201615.68
201513.16
201416.82
201314.38
201213.62
201113.11
201012.55
200911.64
200812.37
200710.58
20069.82
20058.01

Rohto Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Rohto Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Rohto Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Rohto Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Rohto Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Rohto Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Rohto Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Rohto Pharmaceutical Co’s growth potential.

Rohto Pharmaceutical Co Revenue, EBIT and net profit per share

DateRohto Pharmaceutical Co RevenueRohto Pharmaceutical Co EBITRohto Pharmaceutical Co Net Income
2027e360 B undefined0 undefined42.6 B undefined
2026e335.29 B undefined0 undefined39.18 B undefined
2025e305.8 B undefined0 undefined34.67 B undefined
2024270.84 B undefined40.05 B undefined30.94 B undefined
2023238.66 B undefined33.96 B undefined26.38 B undefined
2022199.65 B undefined29.02 B undefined21.13 B undefined
2021181.29 B undefined22.99 B undefined16.74 B undefined
2020188.33 B undefined22.56 B undefined15.41 B undefined
2019183.58 B undefined20.81 B undefined9.8 B undefined
2018171.74 B undefined19.09 B undefined9.29 B undefined
2017154.6 B undefined15.45 B undefined10.01 B undefined
2016167.02 B undefined15.68 B undefined9.1 B undefined
2015151.77 B undefined13.16 B undefined8.63 B undefined
2014143.82 B undefined16.82 B undefined8.95 B undefined
2013129.15 B undefined14.38 B undefined8.09 B undefined
2012120.29 B undefined13.62 B undefined8.18 B undefined
2011115.47 B undefined13.11 B undefined7.97 B undefined
2010113.43 B undefined12.55 B undefined7.77 B undefined
2009110.61 B undefined11.64 B undefined6.14 B undefined
2008108.13 B undefined12.37 B undefined7.53 B undefined
200795.62 B undefined10.58 B undefined6.62 B undefined
200685.85 B undefined9.82 B undefined6.48 B undefined
200573.33 B undefined8.01 B undefined5.44 B undefined

Rohto Pharmaceutical Co stock margins

The Rohto Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Rohto Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Rohto Pharmaceutical Co.
  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Rohto Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Rohto Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Rohto Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Rohto Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Rohto Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Rohto Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Rohto Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Rohto Pharmaceutical Co Margin History

Rohto Pharmaceutical Co Gross marginRohto Pharmaceutical Co Profit marginRohto Pharmaceutical Co EBIT marginRohto Pharmaceutical Co Profit margin
2027e58.07 %0 %11.83 %
2026e58.07 %0 %11.69 %
2025e58.07 %0 %11.34 %
202458.07 %14.79 %11.42 %
202357.58 %14.23 %11.05 %
202258.19 %14.53 %10.58 %
202159 %12.68 %9.24 %
202060.63 %11.98 %8.18 %
201959.66 %11.34 %5.34 %
201858.81 %11.11 %5.41 %
201759.09 %9.99 %6.48 %
201659.73 %9.39 %5.45 %
201559.55 %8.67 %5.69 %
201459.73 %11.7 %6.22 %
201359.12 %11.13 %6.26 %
201258.49 %11.32 %6.8 %
201159.02 %11.36 %6.9 %
201058.87 %11.06 %6.85 %
200958.96 %10.53 %5.55 %
200859.13 %11.44 %6.96 %
200761.08 %11.06 %6.92 %
200662.42 %11.44 %7.55 %
200563.61 %10.93 %7.42 %

Rohto Pharmaceutical Co Aktienanalyse

What does Rohto Pharmaceutical Co do?

Rohto Pharmaceutical Co Ltd is a leading Japanese company in the pharmaceutical and cosmetic products industry, founded in 1899. The company was originally established as a small company to manufacture herbal medicine before undergoing several mergers and acquisitions to become the company we know today. Rohto Pharmaceutical's business model focuses on developing and marketing innovative products for health and beauty. The company has a global reputation for its high-quality products that undergo stringent testing to ensure they are safe and effective. Rohto Pharmaceutical has various business divisions. One of the main areas is the pharmaceutical division, which manufactures medications for various ailments, including ophthalmology, pain relief, and skincare. Another important business area is Rohto Pharmaceutical's cosmetics division, which offers a wide range of facial care products, sunscreen, and whitening products. The company is known for its lotions and emulsions that are based on high-quality ingredients such as vitamin C, hyaluronic acid, and collagen. Over the years, Rohto Pharmaceutical has also launched several groundbreaking products. For example, the company developed the world's first eye drop product for dry eyes. Another groundbreaking invention by Rohto is the invention of menthol cooling effects in eye drops, which are intended to provide a refreshing sensation in the eyes. Rohto Pharmaceutical has developed innovative technologies and production facilities with cleanroom laboratories for pharmaceutical and cosmetic products. The company's technological advancements also include the development of hybrid companies that combine the competencies of pharmacists and cosmetologists, facilitating the development of products for the beauty and health sectors. Although Rohto Pharmaceutical has focused its efforts on the Japanese market, the company has also opened branches in other countries, including the USA, Europe, and Asia. As a result, Rohto offers a wide range of products such as menthol spray, sunscreen, and eye drops that are sold worldwide. Conclusion: Rohto Pharmaceutical is a leading provider of pharmaceutical and cosmetic products. The company has built its reputation based on its innovative products, stringent quality controls, and groundbreaking technologies. Rohto Pharmaceutical has a vision that encompasses "building health, creating beauty, and making life easier." By dividing its business into various divisions, the company is able to offer a wide range of health and beauty products to meet customer needs. Rohto Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Rohto Pharmaceutical Co's EBIT

Rohto Pharmaceutical Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Rohto Pharmaceutical Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Rohto Pharmaceutical Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Rohto Pharmaceutical Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Rohto Pharmaceutical Co Stock

How much did Rohto Pharmaceutical Co achieve in EBIT for the current year?

In the current year, Rohto Pharmaceutical Co has achieved an EBIT of 40.05 B JPY.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Rohto Pharmaceutical Co.

How has the EBIT of Rohto Pharmaceutical Co developed in recent years?

The EBIT of Rohto Pharmaceutical Co has increased by 17.93% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Rohto Pharmaceutical Co?

The EBIT of Rohto Pharmaceutical Co is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Rohto Pharmaceutical Co pay?

Over the past 12 months, Rohto Pharmaceutical Co paid a dividend of 30 JPY . This corresponds to a dividend yield of about 0.89 %. For the coming 12 months, Rohto Pharmaceutical Co is expected to pay a dividend of 32.04 JPY.

What is the dividend yield of Rohto Pharmaceutical Co?

The current dividend yield of Rohto Pharmaceutical Co is 0.89 %.

When does Rohto Pharmaceutical Co pay dividends?

Rohto Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Rohto Pharmaceutical Co?

Rohto Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Rohto Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 32.04 JPY are expected. This corresponds to a dividend yield of 0.95 %.

In which sector is Rohto Pharmaceutical Co located?

Rohto Pharmaceutical Co is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von Rohto Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Rohto Pharmaceutical Co from 12/1/2024 amounting to 15 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Rohto Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Rohto Pharmaceutical Co in the year 2023?

In the year 2023, Rohto Pharmaceutical Co distributed 24 JPY as dividends.

In which currency does Rohto Pharmaceutical Co pay out the dividend?

The dividends of Rohto Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Rohto Pharmaceutical Co

Our stock analysis for Rohto Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Rohto Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.